Some Investors Feel Burned by Clinical-Trial Reports

Roche angered some U.S. shareholders when a medical presentation about a clinical-trial involving the cancer drug Perjeta didn’t bear out the drugmaker’s earlier upbeat disclosures.

from WSJ.com: US Business http://ift.tt/2wWVEP1
via IFTTT